Gene-Editing and RNA Interference in Treating Hepatitis B: A Review

Area of Science:

• Hepatology
• Virology
• Biotechnology

Background:

• Hepatitis B virus (HBV) poses significant global health and economic challenges.
• Current treatments for chronic HBV (interferons, nucleos(t)ide analogs) suppress replication but do not eliminate the virus.
• The 2030 HBV elimination goal requires advancements in diagnostics, prevention, vaccination, and treatment.

Purpose of the Study:

• To review progress in biotechnological approaches for functional and definitive hepatitis B virus treatments.
• To discuss the advantages and challenges of novel therapeutic strategies.
• To highlight the potential of gene-editing tools and RNA interference for HBV viral eradication and functional cure.

Main Methods:

• Review of current literature on gene-editing technologies (ZFNs, TALENs, CRISPR/Cas9) for HBV therapy.
• Analysis of RNA interference-based therapeutics for chronic hepatitis B.
• Discussion of the translational challenges and potential of these advanced biotechnologies.

Main Results:

• Gene-editing tools, including CRISPR/Cas9, show promise for viral eradication but require further safety and efficacy validation.
• RNA interference-based therapeutics are entering human studies for a functional cure, but require larger trials.
• Both approaches represent potential breakthroughs beyond current viral suppression methods.

Conclusions:

• Biotechnological approaches, particularly gene editing and RNA interference, offer new hope for definitive HBV treatment and eradication.
• CRISPR/Cas9 holds significant promise but is in early development stages.
• Continued global vaccination efforts remain critical for hepatitis B prevention.